Physician profile
Isaac C Payne
NPI 1902168552
$163,266.41
in general payments reported to CMS, 2019-2025
18 companies · $105K in 2025
The $105K reported for 2025 was more than what 99% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,622 · 2020: $108 · 2021: $9,816 · 2022: $6,205 · 2023: $15K · 2024: $25K · 2025: $105K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $100K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Travel and Lodging: $19K · Food and Beverage: $5,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $99,600.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,000.00 |
| Travel and Lodging | $19,121.54 |
| Food and Beverage | $5,794.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $162,490.10 | 2019-2025 | Da Vinci Surgical System |
| Covidien Lp | $185.97 | 2019 | |
| Abbvie INC. | $103.94 | 2020-2021 | |
| Tela Bio, INC. | $88.05 | 2023-2024 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Ethicon US, LLC | $75.89 | 2021-2025 | Echelon Flex, Echelon Circular |
| Integra Lifesciences Corporation | $45.62 | 2022 | |
| Trevena, INC. | $40.34 | 2022 | |
| Tersera Therapeutics LLC | $31.21 | 2025 | Zoladex |
| Biom'Up France Sas | $25.47 | 2020 | |
| Pharmacosmos Therapeutics INC. | $24.48 | 2025 | Monoferric |
| Davol INC. | $24.08 | 2020 | |
| Baxter Healthcare | $21.69 | 2021 | |
| Daiichi Sankyo INC. | $21.66 | 2025 | Enhertu |
| Incyte Corporation | $21.27 | 2025 | Monjuvi, Zynyz |
| Regeneron Healthcare Solutions, INC. | $21.19 | 2025 | Libtayo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18.42 | 2019 | |
| Focal Therapeutics, INC. | $16.44 | 2020 | |
| Thd America, INC. | $10.59 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isaac Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.